Skip to main content
Shandong Sito Bio-technology Co., Ltd. logo

Shandong Sito Bio-technology Co., Ltd. — Investor Relations & Filings

Ticker · 300583 ISIN · CNE100002F36 LEI · 836800ENMRCW06CD2U25 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,388 across all filing types
Latest filing 2025-08-25 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300583

About Shandong Sito Bio-technology Co., Ltd.

https://www.sitobiotech.com

Shandong Sito Bio-technology Co., Ltd. specializes in the research, development, and production of steroid hormone intermediates and active pharmaceutical ingredients (APIs). The company utilizes biological fermentation technology to transform phytosterols into critical precursors, including 4-AD, ADD, and 9-OH-AD. These materials are fundamental components for the synthesis of glucocorticoids, sex hormones, and progestogens. By integrating microbial strain engineering with large-scale industrial fermentation, the company provides high-purity raw materials for global drug manufacturing. Its operations emphasize green chemistry and sustainable production methods, maintaining a comprehensive supply chain that spans from raw material processing to the delivery of specialized chemical intermediates.

Recent filings

Filing Released Lang Actions
重大信息内部报告制度（2025年8月）
Governance Information Classification · 95% confidence The document is titled as an internal reporting system for material information of Shandong Saito Biotechnology Co., Ltd., dated August 2025. It outlines procedures, responsibilities, and legal obligations for internal reporting of significant events that could impact the company's securities price. The content is a governance and compliance policy document rather than a financial report, earnings release, or announcement. It does not contain financial data, earnings, or voting results. It is not a report publication announcement or a regulatory filing in the usual sense but rather a governance-related internal control document. Therefore, the most appropriate classification is Governance Information (CGR). The document length is under 5,000 characters, but it is a full policy document, not a brief announcement, so RPA is not suitable.
2025-08-25 Chinese
外部信息报送和使用管理制度（2025年8月）
Governance Information Classification · 95% confidence The document is titled '外部信息报送和使用管理制度' which translates to 'External Information Reporting and Usage Management System'. It outlines internal company policies and procedures regarding the management, approval, and confidentiality of external information reporting. The content focuses on governance, compliance with laws and regulations, and internal controls related to information disclosure and insider information management. There are no financial statements, earnings data, or report publication announcements. The document is a governance-related internal policy document rather than a financial report or announcement. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 1961 characters, which is relatively short but contains substantive governance content, not just an announcement or certification.
2025-08-25 Chinese
审计委员会议事规则（2025年8月）
Governance Information Classification · 95% confidence The document is titled '董事会审计委员会议事规则' which translates to 'Board Audit Committee Meeting Rules'. It details the composition, responsibilities, decision-making procedures, meeting rules, and conflict of interest policies for the audit committee of the board of directors of 山东赛托生物科技股份有限公司. The content focuses on governance structure and internal rules related to the audit committee rather than financial results, audit reports, or announcements. There is no indication that this is an audit report, annual report, or any financial statement. It is a governance document outlining internal rules and procedures for the audit committee, which fits the definition of Governance Information (CGR). The document length is about 5030 characters, and it is a full document, not a brief announcement or certification. Therefore, the appropriate classification is Governance Information (CGR).
2025-08-25 Chinese
年报信息披露重大差错责任追究制度（2025年8月）
Governance Information Classification · 95% confidence The document is titled as a "重大差错责任追究制度" which translates to "Major Error Responsibility Accountability System" related to annual report information disclosure. It outlines the principles, scope, and procedures for accountability regarding significant errors in annual report disclosures, including financial reporting errors and other disclosure mistakes. It references relevant laws and regulations governing annual reports and information disclosure but does not contain actual financial statements or substantive financial data. The document is a policy or governance document about handling errors in annual reports rather than the annual report itself or an announcement of a report. Therefore, it fits best under Governance Information (CGR), as it details internal rules and governance practices related to annual report disclosures.
2025-08-25 Chinese
山东赛托生物科技股份公司章程（2025年8月）
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of 山东赛托生物科技股份有限公司. It contains detailed provisions about the company's organization, shareholder rights, board of directors, management, share issuance, shareholder meetings, voting procedures, and other governance-related rules. It references Chinese company law and securities law, and extensively covers governance structures and procedures. There is no indication that this is an annual report, earnings release, or any financial statement. It is not a notice or announcement but the actual governing document of the company. Therefore, this document fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-08-25 Chinese
关于子公司通过药品GMP符合性检查的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about its subsidiary passing a GMP (Good Manufacturing Practice) compliance inspection issued by a provincial drug regulatory authority. It includes details about the inspection, the product involved, and the impact on the company. The document is short (955 characters) and serves as a regulatory announcement rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed report data. It is not a report publication announcement since it contains substantive information about the inspection result. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about compliance and operational status.
2025-06-30 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.